newsfilter
← Latest News
Business Wire·

Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021

Olutasidenib demonstrated a 33.3% composite complete remission rate (CR/CRh) in people living with R/R AML with the IDH1 mutation Among those with CR/CRh, estimated 18-month survival is 87%; median overall survival has not yet been reached Durati